Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Receivables (2021 - 2025)

Tg Therapeutics (TGTX) has 5 years of Receivables data on record, last reported at $305.6 million in Q4 2025.

  • For Q4 2025, Receivables rose 100.17% year-over-year to $305.6 million; the TTM value through Dec 2025 reached $305.6 million, up 100.17%, while the annual FY2025 figure was $305.6 million, 100.17% up from the prior year.
  • Receivables reached $305.6 million in Q4 2025 per TGTX's latest filing, up from $265.4 million in the prior quarter.
  • Across five years, Receivables topped out at $305.6 million in Q4 2025 and bottomed at $88000.0 in Q2 2022.
  • Average Receivables over 5 years is $86.2 million, with a median of $51.6 million recorded in 2023.
  • Peak YoY movement for Receivables: plummeted 90.55% in 2022, then skyrocketed 19768.18% in 2023.
  • A 5-year view of Receivables shows it stood at $1.4 million in 2021, then plummeted by 93.66% to $88000.0 in 2022, then surged by 64664.77% to $57.0 million in 2023, then skyrocketed by 167.9% to $152.7 million in 2024, then surged by 100.17% to $305.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $305.6 million in Q4 2025, $265.4 million in Q3 2025, and $231.5 million in Q2 2025.